Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,077,000 | 6,524,000 | 4,748,000 | 3,104,000 | 1,325,000 |
| Depreciation Amortization | 803,000 | 3,116,000 | 2,324,000 | 1,533,000 | 756,000 |
| Accounts receivable | -42,000 | -652,000 | -874,000 | -672,000 | -262,000 |
| Other Working Capital | -462,000 | -803,000 | -913,000 | -924,000 | -517,000 |
| Other Operating Activity | -61,000 | 1,381,000 | 966,000 | 423,000 | 115,000 |
| Operating Cash Flow | $1,315,000 | $9,566,000 | $6,251,000 | $3,464,000 | $1,417,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -161,000 | N/A | 46,000 | -44,000 | 8,000 |
| PPE Investments | -399,000 | -2,171,000 | -1,482,000 | -986,000 | -484,000 |
| Net Acquisitions | -19,798,000 | -105,000 | -85,000 | -30,000 | N/A |
| Purchase Of Investment | N/A | -167,000 | N/A | N/A | N/A |
| Sale Of Investment | N/A | 3,000 | N/A | N/A | N/A |
| Other Investing Activity | 34,000 | 18,000 | 12,000 | 8,000 | 6,000 |
| Investing Cash Flow | $-20,324,000 | $-2,422,000 | $-1,509,000 | $-1,052,000 | $-470,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 31,000 | -115,000 | -44,000 | -52,000 | -36,000 |
| Debt Issued | 19,860,000 | 5,000 | 3,000 | 3,000 | 1,000 |
| Debt Repayment | -1,416,000 | -1,504,000 | -1,503,000 | -1,002,000 | -1,001,000 |
| Common Stock Issued | 116,000 | 396,000 | 391,000 | 322,000 | 287,000 |
| Common Stock Repurchased | -180,000 | -893,000 | -591,000 | -286,000 | -280,000 |
| Dividend Paid | -1,098,000 | -4,116,000 | -3,086,000 | -2,055,000 | -1,026,000 |
| Other Financing Activity | 0 | -82,000 | -82,000 | -82,000 | 0 |
| Financing Cash Flow | $17,313,000 | $-6,309,000 | $-4,912,000 | $-3,152,000 | $-2,055,000 |
| Exchange Rate Effect | -23,000 | 71,000 | 65,000 | 75,000 | 24,000 |
| Beginning Cash Position | 8,522,000 | 7,616,000 | 7,616,000 | 7,616,000 | 7,616,000 |
| End Cash Position | 6,803,000 | 8,522,000 | 7,511,000 | 6,951,000 | 6,532,000 |
| Net Cash Flow | $-1,719,000 | $906,000 | $-105,000 | $-665,000 | $-1,084,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,315,000 | 9,566,000 | 6,251,000 | 3,464,000 | 1,417,000 |
| Capital Expenditure | -399,000 | -2,171,000 | -1,482,000 | -986,000 | -484,000 |
| Free Cash Flow | 916,000 | 7,395,000 | 4,769,000 | 2,478,000 | 933,000 |